BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20735202)

  • 21. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
    Niu X; Zou W; Liu C; Zhang N; Fu C
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation.
    Kumar G; Sharma S; Shafiq N; Khuller GK; Malhotra S
    J Pharm Sci; 2012 Jun; 101(6):2165-76. PubMed ID: 22392918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
    Liu Y; Pan J; Feng SS
    Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition.
    Ling G; Zhang P; Zhang W; Sun J; Meng X; Qin Y; Deng Y; He Z
    J Control Release; 2010 Dec; 148(2):241-8. PubMed ID: 20727928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.
    Choi SH; Park TG
    Int J Pharm; 2006 Mar; 311(1-2):223-8. PubMed ID: 16423477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles.
    Kim BS; Kim CS; Lee KM
    Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
    Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
    J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
    Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
    Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
    Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
    J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation.
    Sun S; Liang N; Piao H; Yamamoto H; Kawashima Y; Cui F
    J Microencapsul; 2010; 27(6):471-8. PubMed ID: 20113168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly(DL-lactide-co-glycolide) nanospheres.
    Stevanović M; Maksin T; Petković J; Filipic M; Uskoković D
    Nanotechnology; 2009 Aug; 20(33):335102. PubMed ID: 19636100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
    Mukerjee A; Vishwanatha JK
    Anticancer Res; 2009 Oct; 29(10):3867-75. PubMed ID: 19846921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
    Mistry NP; Desai JL; Thakkar HP
    J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
    Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
    Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral delivery of spray dried PLGA/amifostine nanoparticles.
    Pamujula S; Graves RA; Freeman T; Srinivasan V; Bostanian LA; Kishore V; Mandal TK
    J Pharm Pharmacol; 2004 Sep; 56(9):1119-25. PubMed ID: 15324480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
    Zhao A; Rodgers VG
    J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.